Entire Transcript in Adobe Acrobat Format - National Reference ...

231
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
like that. I just do not -- I do not know where we are in
here. I know there is some underlying issue here that is
not on the table.
(Simultaneous discussion.)
DR. CASSELL: The requirement could be for a
drug company, Rhetaugh.
DR. CHILDRESS: It may be that our chart is not
as clear as it should be because, Eric, I am not sure how
you would say in terms of non potentially beneficial
research with greater than minimal risk that this is a best
interest consideration. I mean, how could --
DR. CASSELL: Well, it is like the people who
participate in Phase I trials.
DR. CHILDRESS: They may want to but how do we
say do it as a best interest consideration?
DR. CASSELL: Well, because the person thinks
that in most instances that some good should come of all
this.
DR. CHILDRESS: That is true for those who
consent but I do not think you want to say that to the
person who does not have the capacity to consent and that
is the category we are talking about.
MR. CAPRON: Eric, it does not fall within the
usual understanding of best interest. It seems to me that